Back

Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 5 Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Zuzana Motovska

Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague (Czechia)

8 More presentations in this session

Presentation thumbnail
Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation
Doctor E. Choi (Seoul, KR)
Abstract
Presentation thumbnail
Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis
Professor G. Lip (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial
Professor M. Blomstrom-Lundqvist (Orebro, SE)
Abstract Slides
Presentation thumbnail
Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program
Professor P. Kirchhof (Hamburg, DE)
Abstract
Presentation thumbnail
Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage
Doctor T. Chao (Taipei, TW)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources